WILMINGTON, DE — Enovis™ has announced the appointment of Davide Visentin as President of its International Surgical division, effective March 1, 2025. Visentin succeeds Dr. Benjamin Reinmann, who has been credited with establishing Enovis as a global leader in the orthopedics industry and integrating the legacy operations of Mathys and LimaCorporate.
Visentin joins Enovis with over 20 years of healthcare experience and a proven track record in the MedTech sector. Previously, he served as Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit at BD, overseeing a team of 700 employees across 50 countries while increasing market share in a competitive landscape. His earlier roles included leading Stryker’s Joint Replacement and Robotic Division in Europe and managing regional operations for Johnson & Johnson Depuy Synthes.
“Under Benjamin Reinmann’s leadership, Enovis has created a world-class International Surgical Business. We sincerely thank Benjamin for his numerous contributions to the growth and success of both Enovis and Mathys, and especially throughout the critical integration of legacy companies Mathys and LimaCorporate,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “We are very excited to welcome Davide to Enovis. He is a dynamic leader with a strong track record of successfully growing businesses, a true passion for orthopedics, and the experience and playbook to take our business to the next level.”
With a computer science degree from the University of Milan, Visentin’s expertise combines technical innovation with operational leadership. Split between Villanova, Italy, and Bettlach, Switzerland, Visentin will focus on driving Enovis’ mission and advancing strategic goals.
“We continue to make great progress with building and growing our International Surgical Business into a global orthopedics leader that is thriving because of our team’s commitment to excellence and to going above and beyond every day to create better together,” added Vogt. “The momentum we created in 2024 puts us in a strong position to advance our strategic goals, continue gaining market share and drive growth through innovation, all with the ultimate goal of improving patient outcomes.”
This leadership transition signals a forward-looking strategy aimed at fostering growth and enhancing patient care worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.